CompletedNot Applicable

PCV13 Effectiveness Study Against Hospitalised VT Pneumococcal CAP in Adults 60 Years and Older

Spain1,821 participantsStarted 2021-03-12

Plain-language summary

Low interventional, prospective, multicentre, hospital-based study involving adults 60 years of age and older hospitalised with CAP at participating sites.

Who can participate

Age range60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥60 years.
✓. Evidence of pneumonia within first 48 hours of hospital admission
✓. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.

Exclusion criteria

✕. Any patient who develops signs and symptoms of pneumonia after being hospitalized for ≥48 hours (either at current hospital, another transferring hospital, or a combination of these).
✕. Previously enrolled subjects readmitted ≤14 days after discharge for their study qualifying admission.
✕. At the time of enrollment, pneumonia has been excluded as the diagnosis or another diagnosis confirmed.

What they're measuring

Number of Participants Categorized as Cases and Controls to Determine Vaccine Effectiveness (VE) of PCV13 Against Hospitalized VT CAP: Overall

Timeframe: Approximately 30 months

Trial details

NCT IDNCT04613375

SponsorPfizer

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2023-10-25

Results submitted2024-10-21

View on ClinicalTrials.gov More Community Acquired Pneumonia (CAP) trials